The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).

    August 2021 in “ Clinical Epidemiology
    Olulade Ayodele, Howard Cabral, David D. McManus, Susan S. Jick
    The study found that men with benign prostatic hyperplasia who were treated with 5-alpha reductase inhibitors (5ARIs), especially over a long-term period, had an increased risk of developing incident idiopathic venous thromboembolism (VTE) compared to those who were treated with alpha-blockers (AB) only.
    Discuss this study in the Community →

    Research cited in this study

    12 / 12 results

    Related Research

    1 / 1 results